Cessatech A/S Stock

Stocks

End-of-day quote NORDIC GROWTH MARKET Other stock markets 07/08/2026			5-day change	1st Jan Change
11.25 ^DKK	-2.17%		+11.94%	-29.51%

07-24	CHMP says no to KemSu, review requested	FW
06-12	Cessatech partners with Rigshospitalet for CT004 development	FW

07-24	CHMP says no to KemSu, review requested	FW
06-12	Cessatech partners with Rigshospitalet for CT004 development	FW
06-12	Cessatech A/S and University Hospital of Copenhagen, Rigshospitalet Enter Collaboration to Advance Intravenous Formulation of Melatonin for Post-Anaesthesia Delirium in Children	CI
05-28	Cessatech narrows losses	FW
05-28	Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
02-27	Cessatech A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-27	Cessatech's Operating Loss Decreased in 2025	FW
02-27	Cessatech A/S Auditor Raises 'Going Concern' Doubt	CI
11-14	Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	Cessatech increases operating loss	FW
31/10/25	Cessatech Nears Launch of Pediatric Pain Medication in US Market	FW
21/08/25	Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
21/08/25	Cessatech Narrows Losses in Second Quarter	FW

08-03	Cessatech: Cessatech – EMA initial KemSu/CT001 opinion Q&A and next steps	PU
08-03	Cessatech - EMA initial KemSu/CT001 opinion Q&A and next steps	AQ
07-24	Cessatech: Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu	PU
07-24	Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu	AQ
06-12	Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children	AQ

Manager	Title	Age	Since
Jes Trygved CEO	Chief Executive Officer	53	01/01/2020
Sarah Margaux Toft-Jørgensen DFI	Director of Finance/CFO	-	01/11/2025
Martin Juhl CTO	Chief Tech/Sci/R&D Officer	-	01/03/2022

Director	Title	Age	Since
Martin Olin CHM	Chairman	57	01/01/2022
Flemming Steen Jensen BRD	Director/Board Member	65	01/01/2020
Charlotte Videbaek BRD	Director/Board Member	64	01/01/2020